Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark

Journal of Medical Economics

Volumn 15, Issue 4, 2012, Pages 695-703

  Langkilde, Lars K ^a   Bergholdt Asmussen, Mikael ^b   Overgaard, Mikkel ^b  

^a Wickstrom and Langkilde ApS   (Denmark)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Anti coagulation; Atrial fibrillation; Cost effectiveness; Dabigatran etexilate; Denmark; Warfarin

Indexed keywords

DABIGATRAN ETEXILATE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG COST; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; STROKE; TREATMENT OUTCOME;

AGED; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; DENMARK; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; MYOCARDIAL INFARCTION; PYRIDINES; RISK ASSESSMENT; STROKE; WARFARIN;

EID: 84861638290     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.673525     Document Type: Article

References (33)

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6 (Pubitemid 39319000)
2. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation: The Rotterdam Study. Eur Heart J 2006; 27:946-53
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections of future prevalence. Circulation 2006;114:119-25 (Pubitemid 44420743)
4. Institute For Rational Pharmacotherapy. Behandling af atrieflimren. Rationel Pharmakoterapi Juni 2008 No 6
5. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-429
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
7. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501 (Pubitemid 29482392)
8. Pengo V, Pegoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006; 21:73-7 (Pubitemid 43231132)
9. Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007;23:83-91 (Pubitemid 46416852)
10. Amouyel P, Mismetti P, Langkilde LK, et al. INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 2009;20:63-9
11. Friberg J, Gislason GH, Gadsbøll N, et al. Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation. J Intern Med 2006;259:173-8
12. Palnum KH, Mehnert F, Andersen G, et al. Medical Prophylaxis following hospitalization for Ischemic Stroke: age-and sex-related differences and relation to mortality. Cerebrovasc Dis 2010;30:556-66
13. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-10
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
15. Sorensen SV, Dewilde S, Singer DE, et al. Cost-effectiveness of warfarin: trial versus ''real-world'' stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-73
16. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105:908-19
17. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-70 (Pubitemid 32537350)
18. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15
19. Statistics Denmark Table HISB8. Life table (2 years tables) by age, sex and life table (1981:1982-2009:2010). Copenhagen: Statistics Denmark. 2010 http://www.statistikbanken.dk. Accessed December 13, 2010
20. Wallentin L, Yusuf S, Ezekowitz MD, et al, on behalf of the RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 6736:61194-4
21. Danish Medicines Agency. Medicinpriser. Copenhagen: Danish Medical Agency, 2011 http://www.medicinpriser.dk. Accessed March 15, 2011
22. Danish Society of Cardiology. Antitrombotisk behandling ved kardiovaskulaere sygdomme. Trombokardiologi. DCS Guidelines. Copenhagen: Danish Society of Cardiology, 2007
23. Ministry of Health. Takstsystem 2011 - vejledning. Copenhagen: Ministry of Health, 2011
24. Danish Medical Association. Honorartabel 01-04-2011. Copenhagen: Danish Medical Association, 2011
25. Porsdal V, Boysen G. Direct costs during the first year after intracerebral hemorrhage. Eur J Neurol 1999;6:449-54 (Pubitemid 29371142)
26. Ghatnekar O, Persson U, Glader EL, et al. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004;20:375-80 (Pubitemid 39079575)
27. Statistics Denmark. Table PRIS8. Consumer price index, annual average (1900=100) by type (1900-2010). Copenhagen: Statistics Denmark, 2010 http://www.statistikbanken.dk. Accessed December 10, 2010
28. Holm T, Lassen JF, Genefke J, et al. Cross-sectorial cooperation between general practice and hospital - shared care elucidated using anticoagulant therapy as an example. Medicinsk Teknologivurdering - puljeprojekter. Copenhagen: National Board of Health, 2006
29. Hvelplund A, Galatius S, Madsen M, et al. Women with acute coronary syndrome are less invasively examined and subsequently less treated than men. Eur Heart J 2010;31:684-90
30. Committee on Health Promotion and Disease. Vi kan leve laengere og sundere. Forebyggelseskommisionens anbefalinger til en styrket forbyggende indsats. Report. Copenhagen: Ministry of Health, Committee on Health Promotion and Disease Prevention, 2009
31. National Board on Health. Referenceprogram for behandling af patienter med apopleksi. Copenhagen: National Board On Health, 2005
32. Ghatnekar O, Glader EL. The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001. Value Health 2008;11:862-8
33. Brü ggenjü rgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health 2007;10:137-4